Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial ...

Despite missing primary endpoints, the endocannabinoid modulator demonstrated encouraging pain score improvements in subgroup ...

Once-daily therapy achieves up to 4.4% placebo-adjusted weight loss, meets all study endpoints and demonstrates favourable ...

Merck’s largest life science investment in Asia-Pacific to date expands regional manufacturing capacity Integrated digital ...

CEO Robert Wonsang Yu shared the company's vision for connecting human and animal health at BIOPLUS-INTERPHEX KOREA 2026 (BIX ...

The timed run also reduced total review time from almost 26 hours for Enveda’s four reviewers to just under three hours, ...

Investigational oral therapy targeting rhodopsin protein misfolding is currently undergoing Phase 1/2 clinical evaluation for ...

Lynk Pharmaceuticals Reports Sustained Phase III Efficacy of Zemprocitinib in Rheumatoid Arthritis Through Week 76 ...

TJ Biopharma Doses First Patient in Phase I Trial of CLDN6 × 4-1BB Bispecific Antibody for Advanced Solid Tumours ...

Accord now holds two pegfilgrastim biosimilars in one market, its in-house Ennumo and the acquired Udenyca. Owning both the ...

MEPSGEN US, Inc., a global innovator in drug delivery system platforms, announced the launch of NanoCalibur® Mini, an ...

Enhertu ® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment ...